Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines skin changes in adults with moderate-to-severe atopic dermatitis who are treated with nemolizumab. Reflectance confocal microscopy is used to noninvasively visualize the epidermis and papillary dermis to identify cellular and structural changes. The study compares imaging findings to what would be expected from the disease course and treatment response in a real-world setting. Participation requires informed consent and affiliation with a social security scheme, and is conducted at a single center in Romans-sur-Isère, France. No interventional procedures beyond standard nemolizumab treatment are described.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 18 years and older.
* Patients with moderate-to-severe Atopic Dermatitis who require systemic treatment with nemolizumab
* Patients affiliated with or entitled to a social security scheme.
* Patients capable of giving informed consent.
* Patients who have received informed information about the study and have co-signed an informed consent form for participation in the study, along with the investigator.

Exclusion Criteria:

* Patients who refuse to participate in the study and legally incapacitated adults
* Patients with an uncontrolled chronic disease that may require corticosteroid courses/treatment.
* Patients with a severe concomitant disease that, in the investigator's opinion, would negatively affect participation in the study.

Where it's running

• Hôpitaux Drôme Nord
  Romans-sur-Isère, Drôme, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new hydrogel for treating mild to moderate eczema

  This study is testing a new hydrogel called zabalafin to see if it helps people with mild to moderate eczema feel better compared to a placebo.

  Recruiting at 12 sites Phase 2 Alphyn Biologics · Brookvale, New South Wales and 11 other locations · NCT06855745

• Herbal ointment for treating atopic dermatitis

  This study is testing a herbal ointment made from a plant to see if it can help people with atopic dermatitis feel better.

  Recruiting Phase 2/3 En Chu Kong Hospital · New Taipei City · NCT06850311

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Global Health Look at Atopic Dermatitis

  A worldwide, multicenter study tests how people with atopic dermatitis access care and treat it, using data from routine medical records.

  Recruiting University of Zurich · Zurich · NCT07659756

• LT-002-158 tablets for moderate-to-severe atopic dermatitis in adults

  This study tests LT-002-158 vs placebo to see if it helps adults with moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Hangzhou, Zhejiang · NCT07895615

• PRA-216 for moderate to severe atopic dermatitis: safety and how it works in the body

  This study tests PRA-216 versus placebo to see if it is safe and helps people with moderate to severe atopic dermatitis.

  Recruiting at 6 sites Phase 2 Prana Therapies Inc · Botany, New South Wales and 8 other locations · NCT07810777

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.